{"id":48879,"date":"2025-11-24T21:47:54","date_gmt":"2025-11-24T13:47:54","guid":{"rendered":"https:\/\/flcube.com\/?p=48879"},"modified":"2025-11-24T21:47:55","modified_gmt":"2025-11-24T13:47:55","slug":"hbm-and-astrazeneca-deepen-adc-tce-collaboration-as-astrazeneca-exercises-license-options","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48879","title":{"rendered":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options"},"content":{"rendered":"\n<p><strong>HBM Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>) announced the renewal and deepening of its global strategic collaboration with <strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including <strong>Antibody\u2011Drug Conjugates (ADCs)<\/strong> and <strong>T\u2011cell Engagers (TCEs)<\/strong> over the next four years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>HBM Holdings (2142.HK) &amp; AstraZeneca<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Expanded global strategic collaboration<\/td><\/tr><tr><td><strong>Initial Deal<\/strong><\/td><td>March\u202f2025<\/td><\/tr><tr><td><strong>Term<\/strong><\/td><td>4\u202fyears (renewal)<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>ADCs and T\u2011cell Engagers (TCEs)<\/td><\/tr><tr><td><strong>AstraZeneca&#8217;s Rights<\/strong><\/td><td>Annual R&amp;D project nomination + option to license<\/td><\/tr><tr><td><strong>HBM&#8217;s Role<\/strong><\/td><td>Discovery and development of nominated programs<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Consistent with March\u202f2025 framework<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Synergy:<\/strong> Leverages HBM&#8217;s <strong>Harbour Mice\u00ae<\/strong> platform for novel antibody generation and AstraZeneca&#8217;s ADC\/TCE clinical development expertise<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> AstraZeneca gains access to <strong>4\u20116 additional programs<\/strong> over the collaboration term<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Option-based structure allows AstraZeneca to validate preclinical data before full licensing commitment<\/li>\n\n\n\n<li><strong>Revenue Visibility:<\/strong> HBM secures <strong>multi\u2011million dollar option fees<\/strong> and potential <strong>$500M+ per program<\/strong> in milestones plus royalties<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Global Market Size (2024)<\/th><th>Growth CAGR<\/th><th>Competitive Position<\/th><\/tr><\/thead><tbody><tr><td><strong>ADC Therapeutics<\/strong><\/td><td>$15.4\u202fbillion<\/td><td>25%<\/td><td>AstraZeneca (Enhertu leader) + HBM novel targets = complementary<\/td><\/tr><tr><td><strong>T-cell Engagers<\/strong><\/td><td>$2.1\u202fbillion<\/td><td>35%<\/td><td>Early\u2011stage but high potential; HBM platform enables rapid discovery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Valuation:<\/strong> Estimated potential deal value of <strong>$2\u20113\u202fbillion<\/strong> across all programs if all options exercised<\/li>\n\n\n\n<li><strong>Next Catalyst:<\/strong> First nomination under expanded terms expected Q1\u202f2026; IND filing for lead ADC candidate <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the HBM\u2011AstraZeneca collaboration expansion, financial terms, and pipeline development. Actual results may differ materially due to risks including program success rates, competitive dynamics, and regulatory changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48882,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,130,770,129,916,871,2790],"class_list":["post-48879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-astrazeneca","tag-az","tag-hbm-holdings","tag-hkg-2142","tag-nasdaq-azn","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options\" \/>\n<meta property=\"og:description\" content=\"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T13:47:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T13:47:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HBM and AstraZeneca Deepen ADC\\\/TCE Collaboration as AstraZeneca Exercises License Options\",\"datePublished\":\"2025-11-24T13:47:54+00:00\",\"dateModified\":\"2025-11-24T13:47:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2406.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"AZ\",\"HBM Holdings\",\"HKG: 2142\",\"NASDAQ: AZN\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48879#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48879\",\"name\":\"HBM and AstraZeneca Deepen ADC\\\/TCE Collaboration as AstraZeneca Exercises License Options - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2406.webp\",\"datePublished\":\"2025-11-24T13:47:54+00:00\",\"dateModified\":\"2025-11-24T13:47:55+00:00\",\"description\":\"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48879\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2406.webp\",\"width\":1080,\"height\":608,\"caption\":\"HBM and AstraZeneca Deepen ADC\\\/TCE Collaboration as AstraZeneca Exercises License Options\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HBM and AstraZeneca Deepen ADC\\\/TCE Collaboration as AstraZeneca Exercises License Options\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options - Insight, China&#039;s Pharmaceutical Industry","description":"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48879","og_locale":"en_US","og_type":"article","og_title":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options","og_description":"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.","og_url":"https:\/\/flcube.com\/?p=48879","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T13:47:54+00:00","article_modified_time":"2025-11-24T13:47:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options","datePublished":"2025-11-24T13:47:54+00:00","dateModified":"2025-11-24T13:47:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48879"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","keywords":["ADC \/ XDC","AstraZeneca","AZ","HBM Holdings","HKG: 2142","NASDAQ: AZN","T cell engager"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48879#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48879","url":"https:\/\/flcube.com\/?p=48879","name":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48879#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","datePublished":"2025-11-24T13:47:54+00:00","dateModified":"2025-11-24T13:47:55+00:00","description":"HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration with AstraZeneca (AZ, NASDAQ: AZN), initially established in March\u202f2025, to jointly discover and develop next\u2011generation biological therapies including Antibody\u2011Drug Conjugates (ADCs) and T\u2011cell Engagers (TCEs) over the next four years.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48879"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48879#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","width":1080,"height":608,"caption":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HBM and AstraZeneca Deepen ADC\/TCE Collaboration as AstraZeneca Exercises License Options"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48879\/revisions"}],"predecessor-version":[{"id":48883,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48879\/revisions\/48883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}